432 results on '"Uharek, L."'
Search Results
2. Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO)
3. Induction of Graft-versus-Leukemia-Activity after Peripheral Blood Progenitor Cell Transplantation (PBPCT)
4. Adoptive Transfer of NK Cells Can Eradicate Residual Leukemia After BMT
5. Natural Killer Cell Alloreactivity Against Acute Leukemia Blasts: The Level of Activity Depends on the Individual Target-Effector Pair
6. S-HAM Salvage Therapy of Relapsed and Refractory AML Followed by Interleukin 2 Postremission Therapy
7. Graft-Versus Leukemia Activity in Experimental Bone Marrow Transplantation: The Impact of Natural Killer Cells and Graft-Versus-Host Disease
8. Graft Rejection After Allogeneic Bone Marrow Transplantation: The Impact of T Cells, Graft-Versus-Host Reaction and Marrow Cell Number
9. Combination of immunoglobulins and natural killer cells in the context of CMV and EBV infection
10. Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial
11. Two Murine Leukemia Models for the Investigation of New Treatment Strategies in Bone Marrow Transplantation
12. Engraftment-Promoting Potential of High-Dose Cytostatic Agents in Allogeneic Bone Marrow Transplantation
13. Comparison of the Engraftment Promoting Potential of High-Dose Cytostatic Agents in Allogeneic Bone Marrow Transplantation
14. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation
15. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
16. Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning
17. Antiviral function and efficacy of polyvalent immunoglobulin products against CMV isolates in different human cell lines
18. Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion
19. ASSOCIATION BETWEEN URIC ACID LEVELS AND ACUTE GRAFT VERSUS HOST DISEASE: PH-P396
20. Prophylactic i.v. Igs in patients with a high risk for CMV after allo-SCT
21. Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy
22. Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation
23. Intensified Strategies to Control Vancomycin-Resistant Enterococci in Immunocompromised Patients
24. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma
25. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation
26. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease
27. CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets
28. Use of natural killer cells in hematopoetic stem cell transplantation
29. Scientific Proceedings Second International Symposium on Cytostatic Drug Resistance
30. BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning
31. Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model
32. HMMR-redirected adoptive T-cell therapy for treatment of refractory acute myeloid leukaemia in context of mismatched stem cell transplantation: O148
33. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice
34. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice
35. Prospective evaluation of SeptiFast test in patients undergoing allogeneic stem cell transplantation: P333
36. Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery
37. Investigating the lysis of small-cell lung cancer cell lines by activated natural killer (NK) cells with a fluorometric assay for NK-cell-mediated cytotoxicity
38. Results of a phase I/II study of dose escalated radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced aggressive non-Hodgkin lymphoma: V1002
39. Allogeneic stem cell transplantation for Hodgkinʼs disease: a retrospective analysis of data from the German stem cell transplantation registry (DRST) and GCTSG: P852
40. Minimum tolerable interval of anti-CD20 90Yttrium ibritumomab-tiuxetan to high-dose chemotherapy with carmustin, etoposide, cytarabine, melphalan and autologous stem cell transplantation for relapsed or refractory aggressive B-NHL: P853
41. Cytogenetic risk groups and minimal residual disease are strong prognostic factors for post-transplant outcome in patients with acute myeloid leukaemia: P730
42. Patients suffering from graft-versus-host disease develop severe organ siderosis - Case report and retrospective analysis: P513
43. Azacitidine and donor lymphocyte infusions as first salvage treatment in patients with acute myeloid leukaemia or myelodysplastic syndromes relapsing after allogeneic stem cell transplantation: interim-analysis from the AZARELA-trial (NCT-00795548): O414
44. Amelioration of intestinal graft-versus-host-disease by the synthetic inhibitory oligonucleotide 2088 in mice: V455
45. Treatment of GvHD with mesenchymal stem cells (MSC): In vitro data favour the combination with MMF and rapamycin and indicate that the simultaneous use of other drugs can strongly impair the immunosuppressive effectiveness of MSC: V840
46. NOD2 Regulates Dendritic Cell Function during Graft-versus-host Disease: V843
47. MyD88-dependent TLR9 sensing aggravates apoptosis during intestinal Graft-versus-Host-Disease in a murine low-intensity conditioning model: V842
48. Inhibition of Neovascularization Simultaneously Ameliorates Graft-versus-host Disease and Decreases Tumor Growth: V839
49. Haploidentical stem cell transplantation with early transfer of highly purified alloreactive CD56+CD3- NK cells offers a promising treatment option for refractory AML: V659
50. Allogeneic Stem Cell Transplantation after Reduced-Intensity Conditioning in Patients with Myelofibrosis: V549
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.